Tags

Type your tag names separated by a space and hit enter

Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Rheumatology (Oxford). 2004 Oct; 43(10):1261-6.R

Abstract

OBJECTIVE

To determine serum levels of soluble cytotoxic T-lymphocyte associated molecule-4 (sCTLA-4) and clinical association in patients with systemic sclerosis (SSc).

METHODS

Serum sCTLA-4 levels from 32 patients with diffuse cutaneous SSc (dSSc) and 27 patients with limited cutaneous SSc (lSSc) were examined by enzyme-linked immunosorbent assay (ELISA). For a longitudinal study, 211 sera from 30 SSc patients were analysed (follow-up 2.1-7.0 yr).

RESULTS

Serum sCTLA-4 levels were elevated in dSSc patients compared with normal controls (n = 41), lSSc patients and patients with active systemic lupus erythematosus (SLE) (n = 23). By contrast, sCTLA-4 levels in patients with lSSc or SLE were normal. SSc patients with elevated sCTLA-4 levels had a shorter disease duration and more frequent presence of digital pitting scars, contracture of phalanges, diffuse pigmentation, pulmonary fibrosis and decreased percentage vital capacity (%VC) than those with normal sCTLA-4 levels. sCTLA-4 levels correlated positively with the extent of skin fibrosis, serum IgG levels and anti-topoisomerase I antibody levels. In a longitudinal study, sCTLA-4 levels decreased on a parallel with improvement of skin sclerosis in five dSSc patients. Skin sclerosis did not improve in two of six dSSc patients with high sCTLA-4 levels throughout the follow-up, while the remaining four patients showed improvement of skin sclerosis.

CONCLUSION

These results suggest that sCTLA-4 correlates with disease severity and activity of SSc and that sCTLA-4 plays a role in immunological abnormalities of SSc, since sCTLA-4 may augment humoral immune responses as well as T-cell responses by interfering with B7-CTLA-4 interactions that induce negative signals in T and B cells.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Sato S
Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. s-sato@med.kanazawa-u.ac.jp
Fujimoto M
No affiliation info available
Hasegawa M
No affiliation info available
Komura K
No affiliation info available
Yanaba K
No affiliation info available
Hayakawa I
No affiliation info available
Matsushita T
No affiliation info available
Takehara K
No affiliation info available

MeSH

Antigens, CDAntigens, DifferentiationAutoantibodiesCTLA-4 AntigenEnzyme-Linked Immunosorbent AssayFemaleHumansImmunosuppressive AgentsLongitudinal StudiesLupus Erythematosus, SystemicMaleMiddle AgedScleroderma, DiffuseSclerosisSeverity of Illness IndexSkinSolubilitySteroidsTime Factors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15266059

Citation

Sato, S, et al. "Serum Soluble CTLA-4 Levels Are Increased in Diffuse Cutaneous Systemic Sclerosis." Rheumatology (Oxford, England), vol. 43, no. 10, 2004, pp. 1261-6.
Sato S, Fujimoto M, Hasegawa M, et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2004;43(10):1261-6.
Sato, S., Fujimoto, M., Hasegawa, M., Komura, K., Yanaba, K., Hayakawa, I., Matsushita, T., & Takehara, K. (2004). Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford, England), 43(10), 1261-6.
Sato S, et al. Serum Soluble CTLA-4 Levels Are Increased in Diffuse Cutaneous Systemic Sclerosis. Rheumatology (Oxford). 2004;43(10):1261-6. PubMed PMID: 15266059.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. AU - Sato,S, AU - Fujimoto,M, AU - Hasegawa,M, AU - Komura,K, AU - Yanaba,K, AU - Hayakawa,I, AU - Matsushita,T, AU - Takehara,K, Y1 - 2004/07/20/ PY - 2004/7/22/pubmed PY - 2004/11/2/medline PY - 2004/7/22/entrez SP - 1261 EP - 6 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 43 IS - 10 N2 - OBJECTIVE: To determine serum levels of soluble cytotoxic T-lymphocyte associated molecule-4 (sCTLA-4) and clinical association in patients with systemic sclerosis (SSc). METHODS: Serum sCTLA-4 levels from 32 patients with diffuse cutaneous SSc (dSSc) and 27 patients with limited cutaneous SSc (lSSc) were examined by enzyme-linked immunosorbent assay (ELISA). For a longitudinal study, 211 sera from 30 SSc patients were analysed (follow-up 2.1-7.0 yr). RESULTS: Serum sCTLA-4 levels were elevated in dSSc patients compared with normal controls (n = 41), lSSc patients and patients with active systemic lupus erythematosus (SLE) (n = 23). By contrast, sCTLA-4 levels in patients with lSSc or SLE were normal. SSc patients with elevated sCTLA-4 levels had a shorter disease duration and more frequent presence of digital pitting scars, contracture of phalanges, diffuse pigmentation, pulmonary fibrosis and decreased percentage vital capacity (%VC) than those with normal sCTLA-4 levels. sCTLA-4 levels correlated positively with the extent of skin fibrosis, serum IgG levels and anti-topoisomerase I antibody levels. In a longitudinal study, sCTLA-4 levels decreased on a parallel with improvement of skin sclerosis in five dSSc patients. Skin sclerosis did not improve in two of six dSSc patients with high sCTLA-4 levels throughout the follow-up, while the remaining four patients showed improvement of skin sclerosis. CONCLUSION: These results suggest that sCTLA-4 correlates with disease severity and activity of SSc and that sCTLA-4 plays a role in immunological abnormalities of SSc, since sCTLA-4 may augment humoral immune responses as well as T-cell responses by interfering with B7-CTLA-4 interactions that induce negative signals in T and B cells. SN - 1462-0324 UR - https://www.unboundmedicine.com/medline/citation/15266059/Serum_soluble_CTLA_4_levels_are_increased_in_diffuse_cutaneous_systemic_sclerosis_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/keh303 DB - PRIME DP - Unbound Medicine ER -